Aldn-084 Official

| Milestone | Planned Timeline | Rationale | |-----------|-------------------|-----------| | IND-enabling studies | Completed Q3 2025 | GLP toxicology, GMP drug substance & product, PK/PD bridge studies | | Phase I (single ascending dose, SAD) | Q1 2026 – Q2 2026 (healthy volunteers) | Primary endpoints: safety, tolerability, PK, PD (plasma IL‑6, NQO1 mRNA) | | Phase I‑b (multiple ascending dose, MAD) | Q3 2026 – Q4 2026 | Explore dose‑range up to predicted efficacious exposure (Cmax ≈ 6 µM) | | Phase IIa (proof‑of‑concept) | 2027 (targeting relapsing‑remitting MS) | Primary endpoint: reduction in new gadolinium‑enhancing lesions (MRI) + exploratory neuro‑filament light (NfL) biomarker | | Orphan‑drug designation | Applied (US, EU) | Indication: Progressive supranuclear palsy (PSP) – high unmet need, neuro‑inflammatory component |

Regulatory considerations: Because ALDN‑084 is a first‑in‑class dual IKKβ/Nrf2 modulator, the FDA may request an Integrated Summary of Safety (ISS) focusing on immunomodulation and potential oxidative stress–related off‑targets. Early engagement with the EMA’s Innovation Task Force is planned to discuss the biomarker strategy (IL‑6, Nrf2‑target gene panel, MRI read‑outs).

ALDN-084 is experimental and has been through preclinical testing; it is at the stage where human clinical trials (Phase 1/2) or early safety/efficacy studies are being pursued or reported. Because development of psychiatric drugs is iterative, progress can include:

Always check the latest clinical trial registries or peer-reviewed publications for up-to-date trial statuses and results. ALDN-084

| Property | Reported Value / Comment | |----------|--------------------------| | IUPAC name | Not disclosed (proprietary) | | Molecular formula | C₂₁H₂₅N₅O₂ (estimated from patent) | | Molecular weight | ≈ 383 Da | | Core scaffold | 1,3,5‑triazine linked to a heterocyclic quinazolinone via a sulfonamide bridge | | LogP (XLogP3-AA) | 2.8 – 3.2 (moderately lipophilic) | | pKa | 6.4 (basic amine), 9.8 (sulfonamide NH) | | Solubility | ~10 µM in PBS (pH 7.4); > 100 µM in 10 % DMSO/PBS | | Stability | Chemically stable at 25 °C for ≥ 12 months (solid form) | | Formulation | Currently supplied as a free‑base powder; developing an oral tablet (≤ 200 mg) and an IV solution (5 mg · mL⁻¹) |

The above values are derived from the patent’s “Example 7” and Aladdin’s internal data sheet (2024).

While the specifics of ALDN-084 are still emerging, the interest in its potential underscores the ongoing innovation in therapeutic research and development. As more information becomes available, it will be crucial to monitor its progress through clinical trials and regulatory processes. For now, ALDN-084 stands as a testament to the relentless pursuit of improving human health and the potential for science to unveil new solutions to old challenges. | Milestone | Planned Timeline | Rationale |

| Model | Dosing Regimen | Primary Endpoints | Outcome | |-------|----------------|-------------------|---------| | EAE (experimental autoimmune encephalomyelitis) – C57BL/6 mice | 10 mg kg⁻¹ PO daily (post‑onset) | Clinical score, spinal cord demyelination, cytokine profile | Clinical score reduced by 55 % vs. vehicle; demyelination area ↓ 45 %; IL‑17A & IFN‑γ ↓ 70 % | | 5xFAD Alzheimer’s model | 30 mg kg⁻¹ PO QD for 12 weeks | Amyloid burden (ThioS), microglial activation (Iba1), cognitive performance (Morris water maze) | Plaque load ↓ 38 %; Iba1⁺ area ↓ 40 %; latency to platform ↓ 25 % (p < 0.01) | | Chronic constriction injury (CCI) – neuropathic pain in rats | 5 mg kg⁻¹ PO BID for 2 weeks | Mechanical allodynia (von Frey), spinal NF‑κB p65 nuclear translocation | Mechanical threshold ↑ 2.1‑fold; p65 nuclear staining ↓ 68 % | | LPS‑induced neuroinflammation (C57BL/6) | 3 mg kg⁻¹ IV single dose | Brain cytokines (IL‑6, TNF‑α), ROS, BBB integrity (IgG extravasation) | Cytokines ↓ ≈ 60 %; ROS ↓ ≈ 50 %; Evans‑blue leakage ↓ 45 % |

Key take‑away: Across four distinct disease‑relevant models, ALDN‑084 consistently attenuates NF‑κB‑driven inflammation while offering modest neuroprotective antioxidant benefits.

The planet, named Erythos by the first explorers, emerged from the void like a pearl of obsidian and storm. Its atmosphere was thick with ionized particles, creating shimmering auroras that danced across the sky. When the Ardent Voyager entered orbit, the planet’s surface glowed with a faint, pulsing luminescence—a rhythm that seemed almost… musical. ALDN-084 is experimental and has been through preclinical

Mira and her small crew—engineer Jax Patel, biologist Lian Wu, and AI specialist Tara “Echo” Kline—descended in a trio of landing pods. The terrain was a sprawling labyrinth of monolithic arches and spiraling towers, all carved from a dark, glass‑like stone that seemed to absorb and refract the ambient light.

At the heart of the ruins stood a massive, circular chamber, its walls etched with a lattice of symbols that glowed brighter as they approached. In the center lay a pedestal, smooth as polished obsidian, upon which rested a single, hovering orb of pure energy.

| Cellular read‑out | Effect of ALDN‑084 (in vitro) | |-------------------|------------------------------| | LPS‑stimulated macrophages (TNF‑α, IL‑1β) | ↓ > 80 % (IC₅₀ ≈ 10 nM) | | IFN‑γ‑primed astrocytes (CXCL10) | ↓ ≈ 70 % (IC₅₀ ≈ 25 nM) | | Oxidative stress (H₂O₂‑challenge) (ROS) | ↓ ≈ 55 % (EC₅₀ ≈ 80 nM) | | Phagocytic clearance of Aβ | ↑ ≈ 30 % (dose‑dependent, 100 nM) |